The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Without protocol reforms, mass vaccinations of the national flock will be unlikely. Astral Foods became the first broiler ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...